Enhancing HSP70-ShRNA transfection in 22RV1 prostate cancer cells by combination of sonoporation, liposomes and HTERT/CMV chimeric promoter.
Enhancing HSP70-ShRNA transfection in 22RV1 prostate cancer cells by combination of sonoporation, liposomes and HTERT/CMV chimeric promoter.
复制标题
DOI：
10.3892/ijo.2013.1921
复制
发表时间：
2013-07
影响因子：
5.2
通讯作者：
Y. Li;Li-Fang Jin;L. Du;Qiusheng Shi;Long Liu;X. Jia;Ying Wu;Fan Li;H. Wang
中科院分区：
文献类型：
--
作者：
Y. Li;Li-Fang Jin;L. Du;Qiusheng Shi;Long Liu;X. Jia;Ying Wu;Fan Li;H. Wang
基因治疗是治疗激素难治性前列腺癌（HRPC）的一种潜在可行的方法，它需要有效的传递系统和靶基因。通过抑制热休克蛋白70 （HSP70）过表达诱导癌细胞凋亡已成为一种有吸引力的癌症治疗策略。在我们的研究中，人类端粒酶逆转录酶（HTERT）表达的高肿瘤特异性促使使用HTERT/巨细胞病毒（CMV）嵌合启动子驱动HSP70-ShRNA表达，诱导HRPC 22RV1细胞凋亡。同时，利用超声靶向微泡破坏（UTMD）诱导的超声穿孔技术，将载有HTERT/CMV启动子的质粒送入细胞。我们的研究结果表明，结合超声穿孔、低剂量脂质体和HTERT/CMV嵌合启动子作为递送系统，具有促进高效基因转移和降低细胞毒性的潜力。
Gene therapy is a potentially viable approach for treating hormone-refractory prostate cancer (HRPC), it requires efficient delivery systems and a target gene. Inducing carcinoma cell apoptosis by inhibition of heat shock protein 70 (HSP70) overexpression has been emerging as an attractive strategy for cancer therapy. In our study, the high tumor-specificity of human telomerase reverse transcriptase (HTERT) expression prompted the use of an HTERT/cytomegalovirus (CMV) chimeric promoter to drive HSP70-ShRNA expression to induce HRPC 22RV1 cell apoptosis. At the same time, sonoporation induced by ultrasound-targeted microbubble destruction (UTMD) was utilized for delivery of plasmid loaded with HTERT/CMV promoter. Our results indicated the combination of sonoporation, low-dose liposomes and HTERT/CMV chimeric promoter as a delivery system has the potential to promote efficient gene transfer with lower cytotoxicity.